| 產品名稱 | VMM18 |
|---|---|
| 商品貨號 | B199302 |
| Organism | Homo sapiens, human |
| Tissue | Melanoma, Lymph Node Metastasis |
| Cell Type | Melanocyte |
| Product Format | frozen |
| Morphology | Epithelial-like |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | Melanoma, Stage IIIB; malignant |
| Age | 45 |
| Gender | Male |
| Ethnicity | Caucasian |
| Applications | Drug screening Development of targeted therapy Development of combination therapy Tumor vaccine development |
| Storage Conditions | liquid nitrogen vapor phase |
| Images |  |
| Derivation | Derived from tumors taken from tumor-involved lymph nodes from patients at the University of Virginia |
| Clinical Data | Primary Site: Back; Metastatic Site: Lymph Node (Left Axilla) ; Male, 45 years of age, Caucasian (Alive at last report, 6/1998, with no evidence of disease.) |
| Antigen Expression | Positives: High VEGF-R2, GP100, Tyrosinase, MAGE-A1, MAGE-A3, NY-ESO-1 |
| HLA Typing | A3,A31,B60,Cw10/3,DR15/4 (HLA: Tumor allelic loss of A31/33) |
| Comments | NRAS: wt CDKN2A Mutation: R58 BRAF Mutation: V600E |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing | Volumes are for a T-75 flask; Adjust accordingly
|
| Cryopreservation | Fetal bovine serum, 90%; DMSO, 10% |
| Culture Conditions | Temperature: 37°C Atmosphere: air, 95%; carbon dioxide (CO2 ), 5% |
| STR Profile | Amelogenin: X D5S818: 12 D13S317: 10,12 D7S820: 9 D16S539: 11 vWA: 15,18 TH01: 6,9.3 TPOX: 8,10 CSF1PO: 10,11 |
| Sterility Tests | Pass |
| Population Doubling Level (PDL) | unknown |
| Population Doubling Capacity | infinite |
| Name of Depositor | Craig L. Slingluff, Jr. M.D. |
| Passage History | Unknown. 2 passages from 10/7/1996 frozen cell line stock, but it is not known how long the line was in culture after being established from tumor tissue obtained in 1994. |
| Year of Origin | 1994 |
| References | Slingluff C, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol. Immunother. 48:661-672, 2000. PubMed: 10752474 Molhoek K, et al. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2. Cancer Res. 68: (11), 2008. PubMed: 18519701 Molhoek K, et al. Comprehensive analysis of RTK activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Res 21(4): 274–284, 2011. PubMed: 21654344 Molhoek K, et al. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J. Trans. Med. 3(39): 2005. PubMed:16255777 Skipper J, et al. Shared epitopes for HLA-A3 = restricted melanoma-reactive hman CTL include a naturally processed epitope from Pmel-I 7/gp100. J. Immunol. 157: 5027-5033, 1996. PubMed: 8943411 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
